New weapons in the war on tuberculosis

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages

  Sharma, Sujata ^a   Yoder, Mark A ^b  

^a RESURRECTION MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug therapy; tuberculosis; vaccine

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; BCG VACCINE; BEDAQUILINE; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; FAS 20013; GATIFLOXACIN; INHA INHIBITORS; ISONIAZID; LINEZOLID; MOXIFLOXACIN; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PLEUROMUTILIN; PNU 10048; PNU 100480; PROTEINASE INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; SQ 609; SQ 641; THIOLACTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BCG VACCINATION; CD4+ T LYMPHOCYTE; COST CONTROL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LUNG TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHY; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SHORT COURSE THERAPY; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 79960504463     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c3509c     Document Type: Review

References (100)

1. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: World Health Organization 2008.
2. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculo-sis complex. Proc Natl Acad Sci. 2002;99:3684-689. (Pubitemid 34252166)
3. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit CareMed. 2003;167:603-662.
4. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247.
5. American Thoracic Society/Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Tho-racic Society/CDC recommendations \- United States, 2001. Am J Respir Crit Care Med. 2001;164:1319-1320.
6. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656-662. (Pubitemid 41052152)
7. Ziegler JE, Edwards ML, Smith DW. Exogenous re-infection in experimental airborne tuberculosis. Tubercle. 1985;66:121-128. (Pubitemid 15011390)
8. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005;171: 1430-145.
9. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit CareMed. 2004;170:1360-1366. (Pubitemid 39657201)
10. Benator D, Bhattacharya M, Bozeman L, et al. Rifapen-tine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a rand-omised clinical trial. Lancet. 2002;360:528-534
11. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A controlled clinical comparison of 6 and 8 months of antituberculous chemotherapy in the treat-ment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis. 1991;143:262-267.
12. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180:558-563.
13. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World. Fourth Global Report. Geneva, Switzerland: World Health Organization, 2008.
14. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs \- worldwide, 2000-2004. MMWR. 2006;55:301-305.
15. Farmer P. DOTS and DOTS-plus: not the only answer. Ann N Y Acad Sci. 2001;953:165-184. (Pubitemid 34072991)
16. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuber-culosis: a cohort study in the Philippines. PLoS Med. 2006;3:e352.
17. Resch SC, Salomon JA, Murray M, et al. Cost-effective-ness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:e241.
18. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279:943-948. (Pubitemid 28136084)
19. Jasmer RM, Seaman CB, Gonzalez LC, et al. Tuberculosis treatment outcomes: directly observed therapy com-pared with self-administered therapy Am J Respir Crit Care Med. 2004;170:561-566. (Pubitemid 39209140)
20. Wandwalo E, Robberstad B, Morkve O. Cost and cost effectiveness of community based and health facility based directly observed treatment of tuberculosis in Dar es Salaam, Tanzania. Cost Eff Resour Alloc. 2005;3:6.
21. Burman WJ, Dalton CB, Cohn DL, et al. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63-70. (Pubitemid 27343601)
22. Grosset J, Truffot-Pernot C, Lacroix C, et al. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother. 1992;36:548-551.
23. Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmo-nary tuberculosis. Initial report. Am J Respir Crit Care Med. 1998;157:1726-1733.
24. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999; 353:1843-1847. (Pubitemid 29251017)
25. Shams H, Weis SE, Klucar P, et al. Enzyme-linked immu-nospot and tuberculin testing to detect latent tubercu-losis infection. Am J Respir Crit Care Med. 2005;172: 1161-1168. (Pubitemid 43066653)
26. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2:200-207. (Pubitemid 28123518)
27. Chang K, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004; 170:1124-1130. (Pubitemid 39488627)
28. Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuber-culosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83-91. (Pubitemid 40863749)
29. Rosenthal IM, Williams K, Tyagi S, et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit CareMed. 2005;172:1457-1462. (Pubitemid 43069821)
30. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tu-berculosis. Am J Respir Crit Care Med. 2006;174:94-101. (Pubitemid 43955249)
31. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006;28:980-985. (Pubitemid 46331968)
32. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47:653-657. (Pubitemid 36158096)
33. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002;46:1022-1025. (Pubitemid 34260345)
34. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxi-floxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-426. (Pubitemid 38134824)
35. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167:1341-1347. (Pubitemid 36609717)
36. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother. 2003;47:2442-2444. (Pubitemid 36919442)
37. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006; 174:331-338. (Pubitemid 44156613)
38. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180:273-280.
39. ISRCTN Website.Controlled comparison of two moxi-floxacin containing treatment shortening regimens in pulmonary tuberculosis, 2008. Available at: http:// www.controlled-trials.com/ISRCTN85595810. Accessed August 5, 2008.
40. U.S. National Institutes of Health Clinical Trials Website. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis, 2008. Available at: http://clinicaltrials.gov/show/ NCT00216385. Accessed August 5, 2008.
41. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuber-culosis. N Engl J Med. 2003;349:1977-1978. (Pubitemid 37409723)
42. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2005;56:180-185.
43. Migliori G, Eker B, Richardson M, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387-393.
44. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily half-dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 2006;58:701-704. (Pubitemid 44288145)
45. U.S. National Institutes of Health Clinical Trials Website. A phase 2a, randomized, 2 arm, open-label, clinical trial of the efficacy of linezolid combined with antitubercu-lous therapy in subjects with extensively drug-resistant (XDR) pulmonary tuberculosis 2008. Available at: http:// www.clinicaltrials.gov/ct2/show/NCT00727844?term= linezolid+AND+tuberculosis&rank=4. Accessed August 5, 2008.
46. Lenaerts AJ, Gruppo V Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005; 49:2294-2301. (Pubitemid 40734457)
47. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2006;50:2621-2625. (Pubitemid 44198679)
48. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52:1522-1524. (Pubitemid 351522025)
49. Diacon A, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54:3402-3407.
50. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466.
51. U.S. National Institutes of Health Clinical Trials Website. Safety, efficacy and pharmacokinetics of OPC-67683 in patients with pulmonary tuberculosis, 2008. Available at: http://www.clinicaltrials.gov/ct2/-show/ NCT00401271?term=OPC-67683+AND+tuberculosis&rank=2. Accessed August 5, 2008
52. U.S. National Institutes of Health Clinical Trials Website. A placebo-controlled, phase 2 trial to evaluate OPC 67683 in patients with pulmonary sputum culture-positive, multidrug-resistant tuberculosis (TB), 2008. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00685360?term=OPC- 67683+AND+tuberculosis& rank=1. Accessed August 5, 2008.
53. Andries K, Verhasselt P, Guillemont J, et al. A diary-lquinolone drug active on the ATP synthase of Myco-bacterium tuberculosis. Science. 2005;307:223-227. (Pubitemid 40116230)
54. Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50:3543-3547. (Pubitemid 44684863)
55. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinolone TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:2831-2835.
56. Diacon A, Pym A, Grobusch M, et al. The Diaryl-quinolone TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-2405.
57. Deidda D, Lampis G, Fioravanti R, et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacte-rium tuberculosis strains. Antimicrob Agents Chemother. 1998;42:3035-3037. (Pubitemid 28501251)
58. Casenghi M, von Schoen-Angerer T Development of New Drugs for TB Chemotherapy: Analysis of the Current Drug Pipeline. Geneva, Switzerland: Medecins Sans Frontieres, 2006
59. Global Alliance for TB Drug Development. Handbook of anti-tuberculosis agents. Tuberculosis. 2008;88:85-170.
60. U.S. National Institutes of Health Clinical Trials Website. Early bactericidal activity (EBA) of SQ109 in adult subjects with pulmonary TB (SQ109EBA), 2011. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01218217. Accessed June 16, 2011.
61. Williams KN, Brickner SJ, Stover CKZ, T, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009;180:371-376.
62. U.S. National Institutes of Health Clinical Trials Website. An open-label, randomized study of PNU-100480 in newly diagnosed, treatment sensitive patients with pulmonary tuberculosis to assess early bactericidal activity (EBA) and whole blood activity (WBA), 2011. Available at: http://clinicaltrials.gov/ct2/show/ NCT01225640. Accessed June 16, 2011.
63. Parrish NM, Houston T, Jones PB, et al. In vitro activity of a novel antimycobacterial compound, N-octanesulfonyla-cetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob Agents Chemother. 2001;45:1143-1150. (Pubitemid 32230995)
64. Parrish NM, Ko CG, Hughes MA, et al. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J Antimicrob Chemother. 2004;54:722-729. (Pubitemid 39386723)
65. Reddy VM, Einck L, Nacy CA. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob Agents Chemother. 2008;52:719-721. (Pubitemid 351170849)
66. Nikonenko B, Reddy V, Protopopova M, et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother. 2009;53:3138-3139.
67. Bogatcheva E, Dubuisson T, Protopopova M, et al. Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother. 2011;66: 578-587.
68. Teo JW, Thayalan P, Beer D, et al. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother. 2006;50:3665-73. (Pubitemid 44684879)
69. Cynamon MH, Alvirez-Freites E, Yeo AET. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother. 2004;53:403-405. (Pubitemid 38239986)
70. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macro-phages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406:735-738.
71. Munoz-Elias EJ, McKinney JD. Mycobacterium tubercu-losis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med. 2005;11:638-644. (Pubitemid 40868304)
72. TB Drug Portfolio. Global Alliance for TB Drug De-velopment, 2011. Available at: http://www.tballiance. org/new/portfolio.php. Accessed June 17, 2011.
73. Tangallapally RP, Yendapally R, Lee RE, et al. Synthesis and evaluation of nitrofuranylamides as novel antitu-berculous agents. J Med Chem. 2004;47:5276-5283. (Pubitemid 39314926)
74. Franco-Paredes C, Rouphael N, del Rio C, et al. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. Int J Infect Dis. 2006;10:93-102. (Pubitemid 43255595)
75. Baumann S, Nasser Eddine A, Kaufmann SH. Progress in tuberculosis vaccine development. Curr Opin Immunol. 2006;18:1-11.
76. Stop TB Partnership Working Group on New TB Vaccines. TB Vaccines Pipeline. Geneva, Switzerland: World Health Organization, 2008.
77. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 2006;4:469-476. (Pubitemid 43771866)
78. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine. 2007;25:14-18. (Pubitemid 44855247)
79. Horwitz MA, Harth G, Dillon BJ, et al. Enhancing the protective efficacy of Mycobacterium bovis BCG vacci-nation against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun. 2005;73:4676-4683. (Pubitemid 41105623)
80. Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004;172:7618-7628. (Pubitemid 38747626)
81. Aeras Global TB Vaccine Foundation Website. Vaccine development, 2011. Available at: http://www.aeras. org/our-approach/vaccine-development.php? portfolio. Accessed June 20, 2011.
82. Tascon RE, Colston MJ, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med. 1996;2: 888-892. (Pubitemid 26296759)
83. Hernandez-Pando R, Pavon L, Arriaga K, et al. Patho-genesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun. 1997;65:3317-3327. (Pubitemid 27342417)
84. Waddell RD, Chintu C, Lein AD, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis. 2000; 30(Suppl 3):S309-S315. (Pubitemid 32250428)
85. Johnson JL, Kamya RM, Okwera A, et al. Randomized controlled trial of Mycobacterium vaccae immunother-apy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis. 2000;181:1304-1312. (Pubitemid 30252534)
86. von Reyn C, Mtei L, Arbeit R, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2010;24:675-685.
87. International Federation of Pharmaceutical Manufac-turers & Associations. Why we need new TB vaccines and what is begin done to create them, 2011. Available at: http://www.ifpma.org/fileadmin/templates/Events/ 2011/RoundTable-TB/pdf/Michel-Greco-Stop-TB-WG- on-New-TB-Vaccines.pdf. Accessed June 20, 2011.
88. Dworski M. Efficacy of bacillus Calmette-Guerin and isoniazid-resistant bacillus Calmette-Guerin with and without isoniazid chemoprophylaxis from day of vacci-nation. I. Experimental findings in guinea pigs. Am Rev Respir Dis. 1973;108:294-300.
89. Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev. 2005;18:687-702. (Pubitemid 41504511)
90. Hawkridge T, Scriba TJ, Gelderbloem S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198:544-552.
91. Horwitz MA, Harth G. A new vaccine against tubercu-losis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 2003;71:1672-1679. (Pubitemid 36368696)
92. Beresford B, Sadoff J. Update on research and develop-ment pipeline: tuberculosis vaccines. Clin Infect Dis. 2010; 50:S178-S183.
93. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003;9:533-539. (Pubitemid 36597098)
94. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacte-rium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest. 2005;115:2472-2479. (Pubitemid 41266209)
95. Stop TB. Tuberculosis candidate vaccines - 2010. Available at: http://wwwstoptb.org/wg/new-vaccines/assets/ documents/ TB%20Vaccine%20Pipeline%2010%20-%2003 %2021%2011.pdf. Accessed June 20, 2011.
96. Velmurugan K, Chen B, Miller JL, et al. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 2007;3:e110.
97. Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Myco-bacterium tuberculosis. J Clin Invest. 2007;117:2279-2288. (Pubitemid 47219573)
98. Edwards KM, Cynamon MH, Voladri RK, et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2001;164:2213-2219. (Pubitemid 34032938)
99. Sambandamurthy VK, Wang X, Chen B, et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tubercu-losis. Nat Med. 2002;8:1171-1174. (Pubitemid 35175974)
100. Sambandamurthy VK, Derrick SC, Hsu T, et al. Myco-bacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine. 2006;24:6309-6320. (Pubitemid 44247236)